Comparative Pharmacology
Head-to-head clinical analysis: MD 76R versus RENO 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MD 76R versus RENO 30.
MD-76R vs RENO-30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MD-76R is a radiopaque contrast agent that contains iodine, which attenuates X-rays, thereby enhancing the contrast of blood vessels and tissues during radiographic procedures. It functions by increasing the absorption of X-rays in areas where it is present, allowing for visualization of vascular structures and organ perfusion.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during radiographic procedures.
2–4 mL/kg intravenously, maximum 150 mL per procedure.
Adults: 30 mL (30 g iodine) intravenously as a single dose for imaging procedures; may repeat once if needed.
None Documented
None Documented
Terminal half-life 1-2 hours; prolonged in renal impairment.
Terminal half-life: 1-2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Primarily renal; 95% eliminated unchanged in urine within 24 hours; <1% fecal.
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent